Covestor Ltd lifted its holdings in Ralliant Corporation (NYSE:RAL – Free Report) by 4,096.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 11,583 shares of the company’s stock after purchasing an additional 11,307 shares during the period. Covestor Ltd’s holdings in Ralliant were worth $590,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Danske Bank A S purchased a new stake in Ralliant during the 4th quarter valued at about $25,000. Westfuller Advisors LLC purchased a new position in Ralliant in the 3rd quarter worth approximately $26,000. V Square Quantitative Management LLC purchased a new position in Ralliant in the 4th quarter worth approximately $26,000. Allworth Financial LP boosted its holdings in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares during the last quarter. Finally, Palisade Asset Management LLC purchased a new stake in shares of Ralliant in the third quarter valued at approximately $26,000.
Ralliant Trading Down 0.3%
Shares of Ralliant stock opened at $58.67 on Wednesday. The stock has a 50 day moving average of $45.95 and a 200 day moving average of $47.77. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The firm has a market capitalization of $6.57 billion and a price-to-earnings ratio of -5.36. Ralliant Corporation has a fifty-two week low of $37.27 and a fifty-two week high of $62.35.
Ralliant Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, June 8th. Ralliant’s payout ratio is -1.83%.
Insider Buying and Selling
In other Ralliant news, SVP Karen M. Bick sold 5,485 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $45.00, for a total value of $246,825.00. Following the transaction, the senior vice president owned 46,756 shares of the company’s stock, valued at $2,104,020. This represents a 10.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Analysts Set New Price Targets
RAL has been the subject of several recent research reports. Morgan Stanley increased their price target on Ralliant from $45.00 to $68.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Barclays upped their target price on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a research note on Monday, April 13th. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Finally, Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.90.
Get Our Latest Stock Analysis on Ralliant
Ralliant Profile
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Featured Stories
- Five stocks we like better than Ralliant
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL – Free Report).
Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.
